Dazoquinast is an imidazoquinoxaline derivative with antiallergic properties, developed by the British company Roussel Laboratories Ltd. Dazoquinast inhibited the IgE-mediated passive cutaneous anaphylaxis in rats passively sensitized to ovalbumen after intravenous and oral administration with ED50s of 0.073 and 0.13 mg/kg respectively.

Decitropine is an anticholinergic and antiulcer agent, developed by Koninklije Pharma FAB NV in the 1960s.

Cimaterol is a chemically stable nonselective agonist β1-, β2-, and β3-adrenoceptors. Cimaterol is used in sport as a stimulant and a fat burner that assists bodybuilders and strength athletes to get rid of body fats. Aside from shedding off fats, another benefit for using cimaterol for athletes is a boost in strength as well as an increase in muscle size or lean body mass. The increase in muscle size has been seen in previous animal studies when cimaterol is used. However, the reason behind the muscle gain is not identified yet, but the body has a very different response compared from taking in anabolic steroids. Experts in the field are saying that the increased nitrogen retention, that is known to cause by cimaterol, maybe the reason behind the muscle gain. Another great thing about Cimaterol is that, it can improve blood flow.

Ciheptolane is spirodibenzocycloalkanedioxalane derivative with analgesic, sedative, antihistaminic, antiserotonic, antiinflammatory, anticonvulsant, and antidepressant activity.

Carmegliptin is a potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. ). DPP-IV is a proline-specific serine protease enzyme that is known to rapidly inactivate two incretin hormones released during food ingestion, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Incretins are essential for regulating both fasting and postprandial plasma glucose by stimulating insulin secretion, supporting β-cell mass, and inhibiting glucagon production by the α-cells to reduce glucose production by the liver. By selectively inhibiting DPP-IV, carmegliptin prolongs the activity of circulating GLP-1 and GIP and improves their potential to prolong the antidiabetic actions. Carmegliptin is indicated for use as monotherapy or in combination with other oral antihyperglycemic agents for the treatment of Type 2 diabetes.

Metrenperone, a 5-hydroxytryptamine blocker, is used in veterinary as an antimyopathic agent. Experiments on rabbits have shown that the drug had positive effects on collagen turnover, remodeling, and organization during acute inflammation and fibroplasia.

IPSALAZIDE is a sulfasalazine analog designed as a colon-specific delivery system for the treatment of inflammatory bowel disease by releasing 5-aminosalicylic acid in the gastrointestinal tract.

Pirenperone, a quinazoline derivative, is a selective antagonist at serotonin receptor 2A binding sites. The liposoluble compound pirenperone has been studied in a variety of behavioral tests including the sensitive d-lysergic acid diethylamide (LSD) cue discrimination assay, in which it served as a potent LSD-antagonist. Pirenperone also proved to be an effective antagonist of serotonin-mediated behavioral responses including the head twitch response thought to be mediated by serotonin receptors.

FIDUXOSIN is a selective alpha1-adrenoceptor antagonist with higher affinity for alpha1A-adrenoceptors and for alpha1D-adrenoceptors than for alpha1B-adrenoceptors. It was in clinical trials for the treatment of benign prostatic hyperplasia.